MolecuLight Showcases Innovative Wound Imaging Technology
MolecuLight, a leader in point-of-care fluorescence imaging technology, will be featured at the American Burn Association (ABA) Annual Meeting. Known for its rapid bacterial detection capabilities, MolecuLight is revolutionizing burn care by offering healthcare professionals a non-invasive way to visualize bacterial presence in wounds during critical evaluations.
Groundbreaking Presentations at the ABA Meeting
At the ABA Annual Meeting, attendees will witness several research presentations that highlight the importance of real-time bacterial imaging in improving clinical outcomes. One of the standout speeches will be given by Dr. Erik Hanson-Viana, a distinguished plastic and reconstructive surgeon. His podium presentation, entitled Fluorescence Imaging-Guided Sampling Provides More Accurate and Actionable Microbiology Compared to the Levine Technique, aims to demonstrate the advantages of using MolecuLight's imaging technology during the treatment of burn wounds.
Understanding the Impact of Cutting-Edge Research
In his presentation, Dr. Hanson-Viana will discuss how MolecuLight-guided sampling enhances patient outcomes by allowing for more effective timing and selection of graft placement in burns. This approach is a significant step forward from traditional techniques, as it offers clinicians actionable insights, enabling improved care and outcomes for patients suffering from extensive burns.
Acknowledging Award-Winning Research
Additionally, Dr. Carlos Daniel Torres García will present his acclaimed research, Bacterial Fluorescence Signals Are Associated with Dermal Regeneration Template Infections in Burn Patients. His findings underscore the connection between bacterial loads identifiable via MolecuLight and the efficacy of regenerative tissue products in burn reconstruction.
Insights into Clinical Practices
This award-winning research was honored as the 2nd best scientific protocol at a highly respected national congress. The implications of these findings are profound, highlighting the necessity of monitoring bacterial levels to prevent complications in burn treatment.
Live Demonstrations of Innovative Technology
MolecuLight invites conference attendees to Booth #626 for live demonstrations. Here, visitors can engage with Dr. Erik Hanson-Viana and other representatives to see firsthand how the MolecuLight i:X and DX imaging systems operate. These ground-breaking devices provide real-time bioburden data, which is essential for guiding clinical decisions.
Enhancing Patient Care Through Technology
Dr. Hanson-Viana shared, "The ability to visualize bacteria in real-time with MolecuLight significantly influences outcomes in burn wound management. This immediate access to valuable information enhances clinical decision-making and ultimately leads to better patient interventions. I'm excited to present this information with my peers at the ABA meeting and discuss its implications for future burn care strategies."
About MolecuLight Inc
MolecuLight Corp. is a pioneering medical imaging company dedicated to improving wound care through innovative technology. The company's flagship products, MolecuLight i:X and DX, are the only class II FDA-cleared point-of-care imaging devices designed for the rapid detection of elevated bacterial burden in wounds. These devices also include capabilities for accurate digital wound measurement, supported by robust clinical documentation including over 100 peer-reviewed publications.
Frequently Asked Questions
What is the focus of MolecuLight at the ABA meeting?
MolecuLight is showcasing its advanced bacterial imaging systems aimed at enhancing burn care and improving clinical outcomes through real-time bacterial visualization.
Who will present at the ABA meeting?
Dr. Erik Hanson-Viana will present on the advantages of fluorescence imaging-guided sampling compared to traditional methods.
What is the significance of Dr. García's research?
His research highlights the correlation between bacterial fluorescence signals and issues in dermal regeneration, emphasizing the need for bacterial monitoring in burn care.
Where can attendees see demonstrations of MolecuLight's technology?
Live demonstrations will occur at Booth #626 during the American Burn Association Annual Meeting.
What makes MolecuLight's products unique?
The MolecuLight imaging devices are the only FDA-cleared systems for real-time detection of bacterial burden, which enhances treatment strategies for burn patients.
